Evidence map›Paper›PMID 36017108›Full record

ArticleMaterials today. Bio2022

J-aggregates albumin-based NIR-II fluorescent dye nanoparticles for cancer phototheranostics.

Bulin Du, Ruiqi Liu, Chunrong Qu, Kun Qian, Yongkuan Suo, Fengxia Wu, Hongda Chen, Xuena Li, Yaming Li, Hongguang Liu and 1 more

Abstract read
In one paragraph

Article in Materials today. Bio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bulin DuDepartment of Nuclear Medicine, The First Hospital of China Medical University, Shenyang, 110001, China.
Ruiqi LiuInstitute of Molecular Medicine, College of Life and Health Sciences, Northeastern University, Shenyang, 110000, China.
Chunrong QuMolecular Imaging Program at Stanford (MIPS), Canary Center at Stanford for Cancer Early Detection, Department of Radiology and Bio-X Program, School of Medicine, Stanford University, California, 94305-5484, USA.
Kun QianMolecular Imaging Program at Stanford (MIPS), Canary Center at Stanford for Cancer Early Detection, Department of Radiology and Bio-X Program, School of Medicine, Stanford University, California, 94305-5484, USA.
Yongkuan SuoInstitute of Molecular Medicine, College of Life and Health Sciences, Northeastern University, Shenyang, 110000, China.
Fengxia WuInstitute of Molecular Medicine, College of Life and Health Sciences, Northeastern University, Shenyang, 110000, China.
Hongda ChenChangchun Institute of Applied Chemistry, Chinese Academy of Science, Changchun, 130000, China.
Xuena LiDepartment of Nuclear Medicine, The First Hospital of China Medical University, Shenyang, 110001, China.
Yaming LiDepartment of Nuclear Medicine, The First Hospital of China Medical University, Shenyang, 110001, China.
Hongguang LiuInstitute of Molecular Medicine, College of Life and Health Sciences, Northeastern University, Shenyang, 110000, China.
Zhen ChengState Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phototheranostics, relying on energy conversions of fluorophores upon excitation, integrating diagnostic fluorescence imaging and photo-driven therapy, represents a promising strategy for cancer precision medicine. Compared with the first near-infrared biological window (NIR-I), fluorophores imaged in the second window (NIR-II, 1000-1700 ​nm) exhibit a higher temporal and spatial resolution and tissue penetration depth. Polymethine cyanine-based dye IR1061 is a typical NIR-II small-molecule organic fluorophore, but its low water solubility and short circulation time limiting its biological applications. Therefore, human serum albumin (HSA) nanoparticles with great biocompatibility and biosafety were employed to fabricate hydrophobic IR1061, which exhibited red-shifted absorption band as typical for J-aggregates. Moreover, IR1061@HSA nanoparticles can be successfully used for NIR-II imaging to noninvasively visualize the tumor vascular networks, as well as real-time intraoperative image-guided tumor resection. Interestingly, benefiting from the high photothermal conversion efficiency brought by J-aggregates, IR1061@HSA nanoparticles were also explored for photothermal therapy (PTT) and cause efficient thermal ablation of tumors. Overall, IR1061@HSA, as a novel J-aggregates albumin-based NIR II dye nanoparticle with high biocompatibility, provides an integrated versatile platform for cancer phototheranostics with promising clinical translation prospects.

Indexed as

Fluorescence imagingHuman serum albuminIR1061NanoparticlesPhotothermal therapySecond near-infrared window

Identifiers

PMID36017108
PMCPMC9395659

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.